With a $425 million upfront payment, Bayer bolstered the company’s women’s healthcare pipeline with the acquisition of U.K.-based KaNDy Therapeutics and an investigational treatment for menopause.
Veru Inc. said a higher dose of the company’s experimental drug reduced hot flashes in men with advanced prostate cancer after six weeks of treatment, in a mid-stage study.
